NON-ALCOHOLIC FATTY LIVER DISEASE

This study tests whether eating only during an 8-hour window each day (and fasting for 16 hours) can help reduce liver fat in people with non-alcoholic fatty liver disease. Participants will also follow a healthy Mediterranean diet and exercise routine. The study will measure liv…

This study tests whether carbocisteine, a drug already used for coughs, can help people with nonalcoholic fatty liver disease (NAFLD). About 46 adults with fatty liver will take the drug to see if it reduces fat buildup in the liver. The goal is to find a safe, affordable treatme…

This study tests whether a type 2 diabetes drug (SGLT2 inhibitor) can reduce liver fat in 40 adolescents aged 16-21 with obesity and non-alcoholic fatty liver disease (NAFLD). Participants will receive either the drug or a placebo for 26 weeks. The main goal is to see if the drug…

This study tests whether a minimally invasive procedure called endoscopic sleeve gastroplasty (ESG), which reduces stomach size by about 70%, can help people with obesity and a serious liver condition called MASH. Participants will be randomly assigned to receive either ESG plus …

This study tests whether time-restricted intermittent fasting can reduce liver fat in non-obese adults (BMI 23-30) with non-alcoholic fatty liver disease (NAFLD). About 25 participants will follow a fasting schedule, and researchers will measure changes in liver fat using advance…

This study looks at whether a healthy lifestyle can help thinking skills and liver health in adults with non-alcoholic fatty liver disease (NAFLD). 45 people aged 18-42 will be placed into one of three groups for six months: general health advice, a Mediterranean diet, or the sam…

This study looks at how the liver responds to food in people with non-alcoholic fatty liver disease (NAFLD) and whether the drug semaglutide can reduce liver fat and damage. About 84 adults with NAFLD and healthy volunteers will participate. Researchers will measure liver fat, en…

This study tests a new medicine called efimosfermin alfa in people with MASH, a liver disease linked to metabolic issues. The goal is to see if the drug is safe and tolerable for patients with moderate liver scarring (stage F2 or F3). About 1,250 adults will receive either the dr…

This study tests a new medicine called efimosfermin alfa in 1,200 adults with MASH (a type of fatty liver disease) and moderate-to-severe liver scarring. The goal is to see if the drug can reduce scarring and resolve liver inflammation without making the disease worse. Participan…

This study looks at whether combining blood tests, genetic markers, and gut bacteria analysis can find liver scarring (fibrosis) earlier than current methods. Researchers will study 1,200 adults referred to a liver clinic. The goal is to catch serious liver disease sooner and red…

This study aims to find new blood-based tests that can accurately detect liver scarring (fibrosis) in people with non-alcoholic fatty liver disease, without needing a painful liver biopsy. Researchers will collect blood samples and ultrasound data from 575 adults with suspected l…

This study looks at how often children with celiac disease also have fatty liver, and whether a gluten-free diet makes a difference. Researchers will review medical records of 91 children to track changes before and after starting the diet. The goal is to better understand the co…

This study looks at how a single dose of the experimental drug efimosfermin alfa behaves in the body and how safe it is for people with different levels of liver damage caused by fatty liver disease. About 32 adults aged 18 to 70 with liver cirrhosis will take part. The goal is t…

This study collects tissue and blood samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, like cell clusters and mouse tumors, to better understand these diseases and test new treatments. The goal is to impro…

This early-stage study tests a single dose of efimosfermin alfa in 30 healthy adults of Chinese, Japanese, and White/European ancestry. The goal is to check safety, how the drug moves through the body, and immune response. No direct treatment benefit is expected; results will gui…

This study looks at whether adults who were born with low birth weight have a higher chance of developing non-alcoholic fatty liver disease (NAFLD). Researchers will compare 250 low-birth-weight adults with 50 normal-birth-weight adults using liver scans and blood tests. The goal…

This study looks at gut bacteria in 3,000 adults with chronic liver diseases like autoimmune hepatitis and fatty liver. Researchers want to find specific bacteria patterns linked to each disease. The goal is to better understand how the gut and liver interact, which may lead to n…

This study aims to find out why some people with fatty liver disease or alcohol-related liver disease develop liver cancer. Researchers will look at genetic markers, immune system factors, and medical images from 710 adults with and without cirrhosis. The goal is to catch early s…

This study aims to find out how many people have non-alcoholic fatty liver disease (NAFLD) and its more serious form, NASH. Researchers will use advanced MRI scans to diagnose the condition in 800 adults from Olmsted County, Minnesota. Participants will be followed over time to t…

This study follows 35 people with severe obesity who are having mini-gastric bypass surgery as part of their routine care. Researchers want to see how the surgery helps improve related health issues like type 2 diabetes, sleep apnea, high blood pressure, and fatty liver disease. …

This study aims to understand how insulin controls sugar and fat production in the liver, comparing healthy adults to those at risk for type 2 diabetes. Participants will receive a single dose of the drug alpelisib or a placebo during two overnight hospital stays. Researchers wil…

This study looks at whether a special ultrasound technique, called endoscopic ultrasound shear wave elastography (EUS-SWE), can better detect liver scarring in people with obesity and fatty liver disease. Standard non-invasive tests are often less accurate in this group. Research…

This study looks at whether a one-week course of the drug diazoxide can reduce how much fat the liver makes in people with obesity, insulin resistance, and a type of fatty liver disease called MASLD. About 25 adults will take either the drug or a placebo, and researchers will mea…

This study looks at how liver cells produce energy in people who have both type 2 diabetes and nonalcoholic fatty liver disease. Researchers will measure liver metabolism before and after 16 weeks of treatment with the diabetes drug pioglitazone. The goal is to understand how the…